The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Dr.Paolo Zamboni has made a huge breakthrough in Multiple Sclerosis research. Sales of Tysabri will go down slow at first, then gain speed. http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20091120/W5_liberation_091121/20091121?s_name=W5 Patients with Multiple Sclerosis and banding together to get tested and treated for Chronic Cerebral Spinal Insufficiency (CCSVI). Clinical trials already show a strong correlation between MS and CCSVI. A surgery (angioplasty or stents) on jugular veins are dramatically reducing symptoms of MS. http://ccsvivictory.club.officelive.com/ConflictsofInterest.aspxThe four new cases of PML only makes things worse.